RepurpOS

Irritable Bowel Syndrome (IBS)

Disease intelligence for Irritable Bowel Syndrome: 111 alterations and 228 ranked therapeutics from curated public databases.

US DALYs1.55MWHO GHE 2021 · all ages
Global DALYs17.03MWHO GHE 2021 · worldwide
US mortality53.1K deaths/yrWHO GHE 2021
Global mortality404.6K deaths/yrWHO GHE 2021 · worldwide
Spontaneous remissionIBS is chronic and remitting; spontaneous 'remission' (symptom resolution without treatment) in ~30-40% at 2 years but…
Best-intervention remissionLow-FODMAP diet: 50-80% symptomatic response; gut-directed hypnotherapy: 70-80% response, durable at 5 years; CBT:…
Gap sizeLarge — effective interventions exist but access to diet counselling, hypnotherapy, and CBT is limited; overreliance…
Primary barrieraccess/practice
Full remission profile →

Disease overview

Alterations
111
Molecular (A)
100
Clinical (B–E)
11
Direct drugs
114
Via biomarker
115
Natural agents
0
Natural products
97
Merged ranked
228
With trial/literature evidence
25

Sources: Open Targets, ClinicalTrials.gov, DGIdb, ChEMBL, PubMed Literature, PubMed NP, ClinicalTrials.gov NP, ChEMBL NP · Pipeline phase 7 · Updated 2026-07-05

Remission & chronicity

Spontaneous remission
IBS is chronic and remitting; spontaneous 'remission' (symptom resolution without treatment) in ~30-40% at 2 years but symptom recurrence common; 10-20% develop persistent daily symptoms; <10% achieve permanent remission
Best-intervention remission
Low-FODMAP diet: 50-80% symptomatic response; gut-directed hypnotherapy: 70-80% response, durable at 5 years; CBT: 60-70% response; rifaximin for IBS-D: 40% vs 31% placebo (modest but significant); neuromodulators (amitriptyline, nortriptyline): 60-70% response in IBS-D/IBS-M
Drug-free remission
—
Relapse after remission
—
Chronicity
—
Gap size
Large — effective interventions exist but access to diet counselling, hypnotherapy, and CBT is limited; overreliance on antispasmodics and antidiarrheals
Primary barrier
access/practice
Barrier detail: Gut-directed hypnotherapy has the strongest long-term evidence of any IBS treatment but virtually no trained therapists; FODMAP diet requires skilled dietitian; pharmacotherapy (linaclotide, plecanatide, eluxadoline) effective but expensive; most patients manage with OTC antispasmodics indefinitely

Last SoC change: 2022 — AGA guidelines updated with neuromodulators as first-line; 2014 linaclotide/lubiprostone approved; 2015 eluxadoline for IBS-D; 2015 rifaximin for IBS-D; antispasmodics (hyoscine, mebeverine) essentially unchanged since 1960s-1970s

Remission data layers: disease_db_100 · source-locked manual data · confidence: high

Identifiers: MONDO: MONDO:0005052 · ORPHA: ORPHA:314373

Right to Try Relevance

Eligibility: This disease meets the federal and state right-to-try legal standard (21 U.S.C. § 360bbb-0a and Montana SB 535): it lacks disease-modifying therapy with indication-specific FDA approval. Patients with Irritable Bowel Syndrome may be eligible to access investigational therapies outside of clinical trials under right-to-try frameworks.
Investigational Agents
98
Phase 3: 22, Phase 2: 66, Phase 1: 10
Most Advanced Phase
Phase 3
Highest dev. stage
Gene Targets
111
Actionable
Pipeline Compounds (Top 6)
Darapladib, Fenretinide, (+)-Menthol, Anise Oil, Antimony, Asimadoline
Legal Standard: Right-to-try requires the disease lacks "adequate approved therapy for that specific disease" (not symptom-management drugs). This distinction means a disease with antidepressants available still qualifies if no FDA approval exists for THAT disease indication.
View Right-to-Try Compendium

Alterations

111 total · Types A (molecular) through E (functional)

NameTypeSubtypeDirection FrequencyEvidenceSourcesLinks
ADORA2A
adenosine A2a receptor
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
ADORA2B
adenosine A2b receptor
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
ALOX5
arachidonate 5-lipoxygenase
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
Abdominal pain Scales & PROs Clinical scale — — Emerging ClinicalTrials.gov —
BLTP1
bridge-like lipid transfer protein family member 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
CACNA1G
calcium voltage-gated channel subunit alpha1 G
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
CACNA1H
calcium voltage-gated channel subunit alpha1 H
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
CACNA1I
calcium voltage-gated channel subunit alpha1 I
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
CADM2
cell adhesion molecule 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
CCKAR
cholecystokinin A receptor
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
CD40
CD40 molecule
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
CELF4
CUGBP Elav-like family member 4
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
CHRM1
cholinergic receptor muscarinic 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
CHRM3
cholinergic receptor muscarinic 3
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
CLCN2
chloride voltage-gated channel 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
COP1
COP1 E3 ubiquitin ligase
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
CTSB
cathepsin B
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
Change From Baseline in Weekly Spontaneous Bowel Movement (SBM) Frequency Over the 4 Week Treatment Period Compared to Placebo and Across Treatment Groups Lab / Clinical Lab value — — Emerging ClinicalTrials.gov —
Change from baseline in stool consistency Lab / Clinical Lab value — — Emerging ClinicalTrials.gov —
DOCK9
dedicator of cytokinesis 9
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
DPYD
dihydropyrimidine dehydrogenase
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
Description of the symptomatology Lab / Clinical Lab value — — Emerging ClinicalTrials.gov —
ELAVL2
ELAV like RNA binding protein 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
EP300
EP300 lysine acetyltransferase
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
ESAM
endothelial cell adhesion molecule
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
Evolution of the severity of functional bowel disorders Lab / Clinical Lab value — — Emerging ClinicalTrials.gov —
FAM120A
family with sequence similarity 120 member A
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
FAM120AOS
family with sequence similarity 120 member A opposite strand
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
GLIS3
GLIS family zinc finger 3
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
GRM7
glutamate metabotropic receptor 7
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
GUCY2C
guanylate cyclase 2C
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
Global clinical evaluation Lab / Clinical Lab value — — Emerging ClinicalTrials.gov —
HRH1
histamine receptor H1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
HRH2
histamine receptor H2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
HTR3A
5-hydroxytryptamine receptor 3A
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
HTR3B
5-hydroxytryptamine receptor 3B
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
HTR3C
5-hydroxytryptamine receptor 3C
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
HTR3D
5-hydroxytryptamine receptor 3D
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
HTR3E
5-hydroxytryptamine receptor 3E
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
HTR4
5-hydroxytryptamine receptor 4
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
IBS symptom severity scale (IBS-SSS) Scales & PROs Clinical scale — — Emerging ClinicalTrials.gov —
Irritable Bowel Syndrome (IBS) Quality of Life Scales & PROs Clinical scale — — Emerging ClinicalTrials.gov —
Irritable Bowel Syndrome Adequate Relief question Lab / Clinical Lab value — — Emerging ClinicalTrials.gov —
LRFN5
leucine rich repeat and fibronectin type III domain containing 5
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
LRP8
LDL receptor related protein 8
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
MECOM
MDS1 and EVI1 complex locus
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
MFHAS1
multifunctional ROCO family signaling regulator 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
MMRN1
multimerin 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
MSRA
methionine sulfoxide reductase A
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
MTNR1A
melatonin receptor 1A
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
MTNR1B
melatonin receptor 1B
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
NCAM1
neural cell adhesion molecule 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
NMUR2
neuromedin U receptor 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
NPAS2
neuronal PAS domain protein 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
OLFM4
olfactomedin 4
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
OPRK1
opioid receptor kappa 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
OPRM1
opioid receptor mu 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PABPC4
poly(A) binding protein cytoplasmic 4
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PCLO
piccolo presynaptic cytomatrix protein
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PDE10A
phosphodiesterase 10A
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PDE1A
phosphodiesterase 1A
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PDE1B
phosphodiesterase 1B
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PDE1C
phosphodiesterase 1C
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PDE2A
phosphodiesterase 2A
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PDE3A
phosphodiesterase 3A
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PDE3B
phosphodiesterase 3B
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PDE4A
phosphodiesterase 4A
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PDE4B
phosphodiesterase 4B
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PDE4C
phosphodiesterase 4C
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PDE4D
phosphodiesterase 4D
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PDE5A
phosphodiesterase 5A
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PDE6A
phosphodiesterase 6A
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PDE6B
phosphodiesterase 6B
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PDE6C
phosphodiesterase 6C
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PDE6D
phosphodiesterase 6D
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PDE6G
phosphodiesterase 6G
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PDE6H
phosphodiesterase 6H
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PDE7A
phosphodiesterase 7A
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PDE7B
phosphodiesterase 7B
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PDE8A
phosphodiesterase 8A
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PDE8B
phosphodiesterase 8B
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PDE9A
phosphodiesterase 9A
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PHF2
PHD finger protein 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PPA2
inorganic pyrophosphatase 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PPARG
peroxisome proliferator activated receptor gamma
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PRLR
prolactin receptor
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PTGS1
prostaglandin-endoperoxide synthase 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PTGS2
prostaglandin-endoperoxide synthase 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
SHISA6
shisa family member 6
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
SLC6A2
solute carrier family 6 member 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
SLC6A4
solute carrier family 6 member 4
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
SLC9A3
solute carrier family 9 member A3
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
SORCS3
sortilin related VPS10 domain containing receptor 3
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
SPATA31D1
SPATA31 subfamily D member 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
STAG1
STAG1 cohesin complex component
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
Stool consistency Lab / Clinical Lab value — — Emerging ClinicalTrials.gov —
TACR2
tachykinin receptor 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
TANK
TRAF family member associated NFKB activator
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
TCF4
transcription factor 4
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
TET2
tet methylcytosine dioxygenase 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
THSD4
thrombospondin type 1 domain containing 4
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
TMEM161B
transmembrane protein 161B
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
TRPA1
transient receptor potential cation channel subfamily A member 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
TRPM8
transient receptor potential cation channel subfamily M member 8
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
TSHZ3
teashirt zinc finger homeobox 3
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
Use of Rescue Medication Lab / Clinical Lab value — — Emerging ClinicalTrials.gov —
VSIG2
V-set and immunoglobulin domain containing 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
WNK2
WNK lysine deficient protein kinase 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
WNT7A
Wnt family member 7A
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
WWOX
WW domain containing oxidoreductase
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
WWP2
WW domain containing E3 ubiquitin protein ligase 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets

FDA-Approved Therapies

Phase 4 agents with regulatory approval for this indication

Drug NameMechanismType
ACETAZOLAMIDE None Gene-targeted
ADENOSINE agonist; agonist Gene-targeted
ALDESLEUKIN Gene-targeted
AMINOPHYLLINE inhibitor Gene-targeted
AMPHETAMINE None Gene-targeted
BALSALAZIDE Gene-targeted
BALSALAZIDE DISODIUM inhibitor Gene-targeted
BEPRIDIL HYDROCHLORIDE blocker Gene-targeted
BICALUTAMIDE None Gene-targeted
CAFFEINE inhibitor; inhibitor Gene-targeted
CAFFEINE CITRATE inhibitor Gene-targeted
CARBACHOL None Gene-targeted
CELECOXIB Gene-targeted
CERULETIDE Gene-targeted
CERULETIDE DIETHYLAMINE agonist Gene-targeted
CIPROFLOXACIN None Gene-targeted
CLOMIPRAMINE None Gene-targeted
DEFIBROTIDE agonist Gene-targeted
DEHYDRATED ALCOHOL Gene-targeted
DIAZEPAM None Gene-targeted
DICHLORPHENAMIDE None Gene-targeted
DIETHYLSTILBESTROL None Gene-targeted
EPIRUBICIN None Gene-targeted
ETHOSUXIMIDE blocker Gene-targeted
ETHOXZOLAMIDE None Gene-targeted
FLAVONE inhibitor Gene-targeted
FLUDARABINE Gene-targeted
FLUMAZENIL None Gene-targeted
GABAPENTIN modulator Gene-targeted
GABAPENTIN ENACARBIL modulator Gene-targeted
HYDROQUINONE Gene-targeted
IMIPRAMINE None Gene-targeted
INDAPAMIDE None Gene-targeted
INDOMETHACIN None Gene-targeted
IRINOTECAN HYDROCHLORIDE Gene-targeted
ISOSORBIDE DINITRATE None Gene-targeted
ISTRADEFYLLINE inhibitor; inhibitor Gene-targeted
LAMOTRIGINE Gene-targeted
LEVODOPA Gene-targeted
MAFENIDE None Gene-targeted
MASOPROCOL Gene-targeted
MECAMYLAMINE None Gene-targeted
MECLOFENAMATE Gene-targeted
MECLOFENAMATE SODIUM inhibitor Gene-targeted
MEFLOQUINE inhibitor Gene-targeted
MESALAMINE inhibitor Gene-targeted
METHAZOLAMIDE None Gene-targeted
METHOTREXATE Gene-targeted
METHOXSALEN None Gene-targeted
METHSUXIMIDE blocker Gene-targeted
METOPROLOL None Gene-targeted
MIANSERIN None Gene-targeted
MIBEFRADIL DIHYDROCHLORIDE blocker Gene-targeted
MILK THISTLE SEED EXTRACT Gene-targeted
MONTELUKAST SODIUM Gene-targeted
NAFTOPIDIL Gene-targeted
NALIDIXIC ACID None Gene-targeted
NICOTINE None Gene-targeted
NORFLOXACIN None Gene-targeted
OFLOXACIN None Gene-targeted
OLSALAZINE SODIUM inhibitor Gene-targeted
OXTRIPHYLLINE inhibitor Gene-targeted
PARAMETHADIONE blocker Gene-targeted
PENTOXIFYLLINE inhibitor Gene-targeted
PHENSUXIMIDE blocker Gene-targeted
PHENYTOIN None Gene-targeted
PIMOZIDE blocker Gene-targeted
PRAZOSIN None Gene-targeted
PREDNISOLONE Gene-targeted
PREGABALIN modulator Gene-targeted
PROGLUMIDE inhibitor Gene-targeted
REGADENOSON agonist Gene-targeted
REGADENOSON ANHYDROUS agonist Gene-targeted
SELENIUM Gene-targeted
SINCALIDE agonist; agonist Gene-targeted
SIROLIMUS None Gene-targeted
SODIUM BICARBONATE Gene-targeted
STREPTOZOCIN Gene-targeted
SULBACTAM None Gene-targeted
SULFASALAZINE inhibitor Gene-targeted
SULOCTIDIL blocker Gene-targeted
TACROLIMUS ANHYDROUS None Gene-targeted
TAZOBACTAM None Gene-targeted
TERODILINE HYDROCHLORIDE blocker Gene-targeted
THEOPHYLLINE inhibitor Gene-targeted
THEOPHYLLINE SODIUM GLYCINATE inhibitor Gene-targeted
TRIMETHADIONE blocker Gene-targeted
TROGLITAZONE None Gene-targeted
VALPROIC ACID Gene-targeted
VERAPAMIL Gene-targeted
VIDARABINE Gene-targeted
ZILEUTON inhibitor; inhibitor Gene-targeted
ZONISAMIDE Gene-targeted

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, and merged ranking. Only agents with registry trials or published clinical literature are shown by default.

DrugTypePhaseEvidence ScoreTrials & literatureSourcesLinks
IMIPRAMINE Small molecule Approved Strong 100
1 Cochrane 1 Meta-analysis 5 Trial pubs 3 RCT
View evidence

Published literature

CT.gov search · Cochrane · PubMed

 Open Targets, ChEMBL ChEMBL Open Targets
ACETAZOLAMIDE Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
ADENOSINE Repurposing Small molecule Approved Strong 95 — DGIdb —
ALDESLEUKIN Repurposing Small molecule Approved Strong 95 — DGIdb —
AMINOPHYLLINE Repurposing Small molecule Approved Strong 95 — DGIdb —
AMPHETAMINE Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
BALSALAZIDE Repurposing Small molecule Approved Strong 95 — DGIdb —
BALSALAZIDE DISODIUM Repurposing Small molecule Approved Strong 95 — DGIdb ChEMBL Open Targets
BEPRIDIL HYDROCHLORIDE Repurposing Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb ChEMBL Open Targets
BICALUTAMIDE Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
CAFFEINE Repurposing Small molecule Approved Strong 95
8 trials 2 Cochrane 1 Meta-analysis 4 Trial pubs 3 RCT
View evidence

Registry trials

  • NCT02450370 — Diets in Symptom Relief and the Influence of Quality of Life in People With Irritable Bowel Syndrome (COMPLETED) NA
  • NCT07560345 — Effect of Neurodynamic Mobilization of Vagus Nerve on Irritable Bowel Syndrome in Women (NOT_YET_RECRUITING) NA
  • NCT07052890 — Curcumin, Vitamin D and Green Tea in IBS-D (COMPLETED) NA
  • NCT05985018 — Traditional Dietary Advice Vs. Mediterranean Diet in IBS (COMPLETED) NA
  • NCT07533500 — Effect of Autogenic Relaxation Training on Irritable Bowel Syndrome In Adult Females (NOT_YET_RECRUITING) NA
  • NCT03423069 — Low FODMAPs Diet vs. Specific Dietary Advice in Patients With IBS Diarrheal Variant (COMPLETED) NA
  • NCT05307185 — Tritordeum-based Foods for IBS Symptoms (COMPLETED) NA
  • NCT05832801 — Effect of Pilates Exercises on Patients With Irritable Bowel Syndrome (COMPLETED) NA

Published literature

CT.gov search · Cochrane · PubMed

 DGIdb —
CAFFEINE CITRATE Repurposing Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
CARBACHOL Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
CELECOXIB Repurposing Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
CERULETIDE Repurposing Small molecule Approved Strong 95 — DGIdb —
CERULETIDE DIETHYLAMINE Repurposing Small molecule Approved Strong 95 — DGIdb ChEMBL Open Targets
CIPROFLOXACIN Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
CLOMIPRAMINE Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
DEFIBROTIDE Repurposing Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
DEHYDRATED ALCOHOL Repurposing Small molecule Approved Strong 95 — DGIdb —
DIAZEPAM Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
EPIRUBICIN Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
ETHOSUXIMIDE Repurposing Small molecule Approved Strong 95
2 trials 3 Trial pubs 3 RCT
View evidence

Registry trials

  • NCT02973542 — Ethosuximide to Treat IBS (COMPLETED) PHASE2
  • NCT04217733 — Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome (RECRUITING) PHASE3

Published literature

CT.gov search · Cochrane · PubMed

 DGIdb —
ETHOXZOLAMIDE Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
FLAVONE Repurposing Small molecule Approved Strong 95 — DGIdb —
FLUDARABINE Repurposing Small molecule Approved Strong 95 — DGIdb —
FLUMAZENIL Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
GABAPENTIN Repurposing Small molecule Approved Strong 95
1 trials 5 Cochrane 2 Meta-analysis 2 Trial pubs 2 RCT
View evidence

Registry trials

  • NCT01678911 — Efficacy of Gralise® for Chronic Pelvic Pain (TERMINATED) PHASE4

Published literature

CT.gov search · Cochrane · PubMed

 DGIdb —
GABAPENTIN ENACARBIL Repurposing Small molecule Approved Strong 95
1 trials
View evidence

Registry trials

  • NCT01678911 — Efficacy of Gralise® for Chronic Pelvic Pain (TERMINATED) PHASE4

CT.gov search · Cochrane · PubMed

 DGIdb —
HYDROQUINONE Repurposing Small molecule Approved Strong 95 — DGIdb —
INDAPAMIDE Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
INDOMETHACIN Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
IRINOTECAN HYDROCHLORIDE Repurposing Small molecule Approved Strong 95 — DGIdb —
ISOSORBIDE DINITRATE Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
ISTRADEFYLLINE Repurposing Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
LAMOTRIGINE Repurposing Small molecule Approved Strong 95 — DGIdb —
LEVODOPA Repurposing Small molecule Approved Strong 95
4 pubs
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
MAFENIDE Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
MASOPROCOL Repurposing Small molecule Approved Strong 95 — DGIdb —
MECAMYLAMINE Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
MECLOFENAMATE Repurposing Small molecule Approved Strong 95 — DGIdb —
MECLOFENAMATE SODIUM Repurposing Small molecule Approved Strong 95 — DGIdb ChEMBL Open Targets
MEFLOQUINE Repurposing Small molecule Approved Strong 95 — DGIdb —
MESALAMINE Repurposing Small molecule Approved Strong 95 — DGIdb —
METHAZOLAMIDE Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
METHOTREXATE Repurposing Small molecule Approved Strong 95 — DGIdb —
METHOXSALEN Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
METHSUXIMIDE Repurposing Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
METOPROLOL Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
MIANSERIN Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
MIBEFRADIL DIHYDROCHLORIDE Repurposing Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb ChEMBL Open Targets
MILK THISTLE SEED EXTRACT Repurposing Small molecule Approved Strong 95 — DGIdb —
MONTELUKAST SODIUM Repurposing Small molecule Approved Strong 95 — DGIdb —
NAFTOPIDIL Repurposing Small molecule Approved Strong 95 — DGIdb ChEMBL Open Targets
NALIDIXIC ACID Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
NICOTINE Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
NORFLOXACIN Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
OFLOXACIN Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
OLSALAZINE SODIUM Repurposing Small molecule Approved Strong 95 — DGIdb ChEMBL Open Targets
OXTRIPHYLLINE Repurposing Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
PARAMETHADIONE Repurposing Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
PENTOXIFYLLINE Repurposing Small molecule Approved Strong 95
2 trials 1 Trial pubs 1 RCT
View evidence

Registry trials

  • NCT04217733 — Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome (RECRUITING) PHASE3
  • NCT01542268 — Effect of Pentoxifylline on Tight Junctions (TJs) of Intestinal Mucosa in Patients With Irritable Bowel Syndrome(IBS) (UNKNOWN) PHASE4

Published literature

CT.gov search · Cochrane · PubMed

 DGIdb —
PHENSUXIMIDE Repurposing Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
PHENYTOIN Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
PIMOZIDE Repurposing Small molecule Approved Strong 95 — DGIdb —
PRAZOSIN Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
PREDNISOLONE Repurposing Small molecule Approved Strong 95 — DGIdb —
PREGABALIN Repurposing Small molecule Approved Strong 95
3 trials 1 Cochrane 2 Meta-analysis 5 Trial pubs 5 RCT
View evidence

Registry trials

  • NCT07635394 — Efficacy of Pregabalin for Patients With Irritable Bowel Syndrome (RECRUITING) NA
  • NCT00977197 — A Placebo-Controlled Trial of Pregabalin (Lyrica) for Irritable Bowel Syndrome (COMPLETED) PHASE2
  • NCT01331213 — Pregabalin on Colonic Motor and Sensory Function in Constipation Predominant Irritable Bowel Syndrome (COMPLETED) PHASE4

Published literature

CT.gov search · Cochrane · PubMed

 DGIdb —
PROGLUMIDE Repurposing Small molecule Approved Strong 95 — DGIdb —
REGADENOSON Repurposing Small molecule Approved Strong 95 — DGIdb ChEMBL Open Targets
REGADENOSON ANHYDROUS Repurposing Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
SELENIUM Repurposing Small molecule Approved Strong 95 — DGIdb —
SINCALIDE Repurposing Small molecule Approved Strong 95 — DGIdb —
SIROLIMUS Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
SODIUM BICARBONATE Repurposing Small molecule Approved Strong 95 — DGIdb —
STREPTOZOCIN Repurposing Small molecule Approved Strong 95 — DGIdb —
SULBACTAM Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
SULFASALAZINE Repurposing Small molecule Approved Strong 95 — DGIdb —
SULOCTIDIL Repurposing Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb ChEMBL Open Targets
TACROLIMUS ANHYDROUS Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
TAZOBACTAM Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
TERODILINE HYDROCHLORIDE Repurposing Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb ChEMBL Open Targets
THEOPHYLLINE Repurposing Small molecule Approved Strong 95
3 pubs
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
THEOPHYLLINE SODIUM GLYCINATE Repurposing Small molecule Approved Strong 95 — DGIdb ChEMBL Open Targets
TRIMETHADIONE Repurposing Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
TROGLITAZONE Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
VALPROIC ACID Repurposing Small molecule Approved Strong 95 — DGIdb —
VERAPAMIL Repurposing Small molecule Approved Strong 95
1 trials
View evidence

Registry trials

  • NCT00552565 — Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D) (COMPLETED) PHASE3

CT.gov search · Cochrane · PubMed

 DGIdb —
VIDARABINE Repurposing Small molecule Approved Strong 95 — DGIdb —
ZILEUTON Repurposing Small molecule Approved Strong 95 — DGIdb —
ZONISAMIDE Repurposing Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
(+)-MENTHOL Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
ANISE OIL Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
ANTIMONY Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
ASIMADOLINE Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
BIFIDOBACTERIUM SPP. Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
CILANSETRON Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
DESIPRAMINE Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
DEXLOXIGLUMIDE Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
EBASTINE Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
ETHOSUXIMIDE Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
IBODUTANT Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
MELATONIN Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
MENTHOL Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
MESALAMINE Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
MOSAPRIDE Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
PENTOXIFYLLINE Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
PEPPERMINT OIL Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
PINAVERIUM BROMIDE Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
RENZAPRIDE Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
RIFAXIMIN Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
DARAPLADIB Repurposing Small molecule Phase III Moderate 70 — ChEMBL ChEMBL Open Targets
FENRETINIDE Repurposing Small molecule Phase III Moderate 70 — ChEMBL ChEMBL Open Targets
AMITRIPTYLINE Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
BOS-589 Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
BUTYRIC ACID Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
CHENODIOL Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
CITALOPRAM Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
COLESEVELAM Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
CROFELEMER Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
DDP-225 Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
DEXTOFISOPAM Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
DEXTROMETHORPHAN Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
DNK333 Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
DOXEPIN Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
DRONABINOL Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
EMICERFONT Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
ESCITALOPRAM Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
EZLOPITANT Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
FABESETRON Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
FENTANYL Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
GLUTAMINE Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
ITOPRIDE Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
LIDOCAINE Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
MAGNESIUM PIDOLATE Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
MILNACIPRAN Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
NALOXONE Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
NORTRIPTYLINE Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
OLSALAZINE SODIUM Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
ONO-2952 Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
ORP-101 Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
PD-217014 Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
PIBOSEROD HYDROCHLORIDE Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
PLANTAGO SEED Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
PREGABALIN Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
PSILOCYBIN Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
PUMOSETRAG Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
RANOLAZINE Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
REZATOMIDINE Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
RIFAMYCIN SODIUM Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
RIMEGEPANT Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
SB-705498 Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
SIMPINICLINE Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
ST. JOHN'S WORT Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
TALNETANT Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
THIOCOLCHICOSIDE Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
TOFISOPAM Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
VIBEGRON Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
BLESELUMAB Repurposing Small molecule Phase II Emerging 50 — DGIdb ChEMBL Open Targets
CE-326597 Repurposing Small molecule Phase II Emerging 50 — DGIdb —
DEXLOXIGLUMIDE Repurposing Small molecule Phase II Emerging 50 — DGIdb —
ISCALIMAB Repurposing Small molecule Phase II Emerging 50 — DGIdb —
MONOCLONAL ANTIBODY SGN-14 Repurposing Small molecule Phase II Emerging 50 — DGIdb —
ALPRENOLOL Repurposing Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
AMIFLOXACIN Repurposing Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
BROLAMFETAMINE Repurposing Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
CARZENIDE Repurposing Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
DIFLOXACIN Repurposing Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
DIMECAMINE Repurposing Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
ELLAGIC ACID Repurposing Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
ENISOPROST Repurposing Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
FENCAMFAMIN Repurposing Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
FLEROXACIN Repurposing Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
IDOXIFENE Repurposing Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
LYSERGIDE Repurposing Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
MERAFLOXACIN Repurposing Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
TENAMFETAMINE Repurposing Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
ZIDAPAMIDE Repurposing Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
ACETYLCYSTEINE Small molecule Phase I Emerging 35 — Open Targets ChEMBL Open Targets
DA-6886 Small molecule Phase I Emerging 35 — Open Targets ChEMBL Open Targets
MEXILETINE Small molecule Phase I Emerging 35 — Open Targets ChEMBL Open Targets
NIACIN Small molecule Phase I Emerging 35 — Open Targets ChEMBL Open Targets
NITAZOXANIDE Small molecule Phase I Emerging 35 — Open Targets ChEMBL Open Targets
OLORINAB Small molecule Phase I Emerging 35 — Open Targets ChEMBL Open Targets
POLYETHYLENE GLYCOL Small molecule Phase I Emerging 35 — Open Targets ChEMBL Open Targets
ROSE-010 Small molecule Phase I Emerging 35 — Open Targets ChEMBL Open Targets
TU-100 Small molecule Phase I Emerging 35 — Open Targets ChEMBL Open Targets
VARENICLINE Small molecule Phase I Emerging 35 — Open Targets ChEMBL Open Targets
ALOSETRON Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
ALOSETRON HYDROCHLORIDE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
ALVERINE CITRATE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
CALCIUM POLYCARBOPHIL Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
CARAWAY OIL Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
CHAMOMILE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
CHARCOAL, ACTIVATED Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
CLIDINIUM Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
CLINDAMYCIN PHOSPHATE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
DICYCLOMINE HYDROCHLORIDE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
DROTAVERINE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
ELUXADOLINE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
ESKETAMINE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
LACTASE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
LINACLOTIDE Biologic Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
LOPERAMIDE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
LUBIPROSTONE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
MEBEVERINE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
METHANTHELINE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
NEOMYCIN Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
ORNIDAZOLE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
OTILONIUM BROMIDE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
OXITRIPTAN Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
PINAVERIUM Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
PIROMELATINE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
PLECANATIDE Biologic Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
PRIFINIUM Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
PRUCALOPRIDE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
QUETIAPINE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
RAMOSETRON HYDROCHLORIDE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
SENNA Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
SIMETHICONE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
SULFASALAZINE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
TEGASEROD Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
TEGASEROD MALEATE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
TENAPANOR Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
TENAPANOR HYDROCHLORIDE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
TRIMEBUTINE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
DrugTypePhaseEvidence ScoreTrials & literatureSourcesLinks
(+)-MENTHOL Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
ANISE OIL Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
ANTIMONY Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
ASIMADOLINE Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
BIFIDOBACTERIUM SPP. Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
CILANSETRON Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
DESIPRAMINE Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
DEXLOXIGLUMIDE Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
EBASTINE Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
ETHOSUXIMIDE Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
IBODUTANT Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
MELATONIN Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
MENTHOL Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
MESALAMINE Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
MOSAPRIDE Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
PENTOXIFYLLINE Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
PEPPERMINT OIL Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
PINAVERIUM BROMIDE Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
RENZAPRIDE Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
RIFAXIMIN Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
AMITRIPTYLINE Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
BOS-589 Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
BUTYRIC ACID Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
CHENODIOL Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
CITALOPRAM Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
COLESEVELAM Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
CROFELEMER Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
DDP-225 Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
DEXTOFISOPAM Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
DEXTROMETHORPHAN Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
DNK333 Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
DOXEPIN Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
DRONABINOL Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
EMICERFONT Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
ESCITALOPRAM Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
EZLOPITANT Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
FABESETRON Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
FENTANYL Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
GLUTAMINE Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
IMIPRAMINE Small molecule Phase II Emerging 60
1 Cochrane 1 Meta-analysis 5 Trial pubs 3 RCT
View evidence

Published literature

CT.gov search · Cochrane · PubMed

 Open Targets ChEMBL Open Targets
ITOPRIDE Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
LIDOCAINE Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
MAGNESIUM PIDOLATE Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
MILNACIPRAN Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
NALOXONE Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
NORTRIPTYLINE Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
OLSALAZINE SODIUM Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
ONO-2952 Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
ORP-101 Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
PD-217014 Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
PIBOSEROD HYDROCHLORIDE Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
PLANTAGO SEED Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
PREGABALIN Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
PSILOCYBIN Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
PUMOSETRAG Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
RANOLAZINE Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
REZATOMIDINE Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
RIFAMYCIN SODIUM Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
RIMEGEPANT Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
SB-705498 Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
SIMPINICLINE Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
ST. JOHN'S WORT Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
TALNETANT Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
THIOCOLCHICOSIDE Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
TOFISOPAM Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
VIBEGRON Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
ACETYLCYSTEINE Small molecule Phase I Emerging 35 — Open Targets ChEMBL Open Targets
DA-6886 Small molecule Phase I Emerging 35 — Open Targets ChEMBL Open Targets
MEXILETINE Small molecule Phase I Emerging 35 — Open Targets ChEMBL Open Targets
NIACIN Small molecule Phase I Emerging 35 — Open Targets ChEMBL Open Targets
NITAZOXANIDE Small molecule Phase I Emerging 35 — Open Targets ChEMBL Open Targets
OLORINAB Small molecule Phase I Emerging 35 — Open Targets ChEMBL Open Targets
POLYETHYLENE GLYCOL Small molecule Phase I Emerging 35 — Open Targets ChEMBL Open Targets
ROSE-010 Small molecule Phase I Emerging 35 — Open Targets ChEMBL Open Targets
TU-100 Small molecule Phase I Emerging 35 — Open Targets ChEMBL Open Targets
VARENICLINE Small molecule Phase I Emerging 35 — Open Targets ChEMBL Open Targets
ALOSETRON Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
ALOSETRON HYDROCHLORIDE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
ALVERINE CITRATE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
CALCIUM POLYCARBOPHIL Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
CARAWAY OIL Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
CHAMOMILE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
CHARCOAL, ACTIVATED Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
CLIDINIUM Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
CLINDAMYCIN PHOSPHATE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
DICYCLOMINE HYDROCHLORIDE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
DROTAVERINE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
ELUXADOLINE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
ESKETAMINE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
LACTASE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
LINACLOTIDE Biologic Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
LOPERAMIDE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
LUBIPROSTONE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
MEBEVERINE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
METHANTHELINE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
NEOMYCIN Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
ORNIDAZOLE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
OTILONIUM BROMIDE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
OXITRIPTAN Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
PINAVERIUM Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
PIROMELATINE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
PLECANATIDE Biologic Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
PRIFINIUM Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
PRUCALOPRIDE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
QUETIAPINE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
RAMOSETRON HYDROCHLORIDE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
SENNA Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
SIMETHICONE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
SULFASALAZINE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
TEGASEROD Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
TEGASEROD MALEATE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
TENAPANOR Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
TENAPANOR HYDROCHLORIDE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
TRIMEBUTINE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
DrugTypePhaseEvidence ScoreTrials & literatureSourcesLinks
ACETAZOLAMIDE Repurposing via ADORA2A Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
ADENOSINE Repurposing via ADORA2A Small molecule Approved Strong 95 — DGIdb —
ALDESLEUKIN Repurposing via CD40 Small molecule Approved Strong 95 — DGIdb —
AMINOPHYLLINE Repurposing via ADORA2A Small molecule Approved Strong 95 — DGIdb —
AMPHETAMINE Repurposing via ADORA2A Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
BALSALAZIDE Repurposing via ALOX5 Small molecule Approved Strong 95 — DGIdb —
BALSALAZIDE DISODIUM Repurposing via ALOX5 Small molecule Approved Strong 95 — DGIdb ChEMBL Open Targets
BEPRIDIL HYDROCHLORIDE Repurposing via CACNA1G Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb ChEMBL Open Targets
BICALUTAMIDE Repurposing via ADORA2A Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
CAFFEINE Repurposing via ADORA2A Small molecule Approved Strong 95
8 trials 2 Cochrane 1 Meta-analysis 4 Trial pubs 3 RCT
View evidence

Registry trials

  • NCT02450370 — Diets in Symptom Relief and the Influence of Quality of Life in People With Irritable Bowel Syndrome (COMPLETED) NA
  • NCT07560345 — Effect of Neurodynamic Mobilization of Vagus Nerve on Irritable Bowel Syndrome in Women (NOT_YET_RECRUITING) NA
  • NCT07052890 — Curcumin, Vitamin D and Green Tea in IBS-D (COMPLETED) NA
  • NCT05985018 — Traditional Dietary Advice Vs. Mediterranean Diet in IBS (COMPLETED) NA
  • NCT07533500 — Effect of Autogenic Relaxation Training on Irritable Bowel Syndrome In Adult Females (NOT_YET_RECRUITING) NA
  • NCT03423069 — Low FODMAPs Diet vs. Specific Dietary Advice in Patients With IBS Diarrheal Variant (COMPLETED) NA
  • NCT05307185 — Tritordeum-based Foods for IBS Symptoms (COMPLETED) NA
  • NCT05832801 — Effect of Pilates Exercises on Patients With Irritable Bowel Syndrome (COMPLETED) NA

Published literature

CT.gov search · Cochrane · PubMed

 DGIdb —
CAFFEINE CITRATE Repurposing via ADORA2A Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
CARBACHOL Repurposing via ADORA2A Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
CELECOXIB Repurposing via CACNA1G Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
CERULETIDE Repurposing via CCKAR Small molecule Approved Strong 95 — DGIdb —
CERULETIDE DIETHYLAMINE Repurposing via CCKAR Small molecule Approved Strong 95 — DGIdb ChEMBL Open Targets
CIPROFLOXACIN Repurposing via ADORA2A Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
CLOMIPRAMINE Repurposing via ADORA2A Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
DEFIBROTIDE Repurposing via ADORA2A Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
DEHYDRATED ALCOHOL Repurposing via CADM2 Small molecule Approved Strong 95 — DGIdb —
DIAZEPAM Repurposing via ADORA2A Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing via ADORA2A Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing via ADORA2A Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
EPIRUBICIN Repurposing via ADORA2A Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
ETHOSUXIMIDE Repurposing via CACNA1G Small molecule Approved Strong 95
2 trials 3 Trial pubs 3 RCT
View evidence

Registry trials

  • NCT02973542 — Ethosuximide to Treat IBS (COMPLETED) PHASE2
  • NCT04217733 — Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome (RECRUITING) PHASE3

Published literature

CT.gov search · Cochrane · PubMed

 DGIdb —
ETHOXZOLAMIDE Repurposing via ADORA2A Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
FLAVONE Repurposing via ADORA2A Small molecule Approved Strong 95 — DGIdb —
FLUDARABINE Repurposing via CD40 Small molecule Approved Strong 95 — DGIdb —
FLUMAZENIL Repurposing via ADORA2A Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
GABAPENTIN Repurposing via CACNA1G Small molecule Approved Strong 95
1 trials 5 Cochrane 2 Meta-analysis 2 Trial pubs 2 RCT
View evidence

Registry trials

  • NCT01678911 — Efficacy of Gralise® for Chronic Pelvic Pain (TERMINATED) PHASE4

Published literature

CT.gov search · Cochrane · PubMed

 DGIdb —
GABAPENTIN ENACARBIL Repurposing via CACNA1G Small molecule Approved Strong 95
1 trials
View evidence

Registry trials

  • NCT01678911 — Efficacy of Gralise® for Chronic Pelvic Pain (TERMINATED) PHASE4

CT.gov search · Cochrane · PubMed

 DGIdb —
HYDROQUINONE Repurposing via CD40 Small molecule Approved Strong 95 — DGIdb —
IMIPRAMINE Repurposing via ADORA2A Small molecule Approved Strong 95
1 Cochrane 1 Meta-analysis 5 Trial pubs 3 RCT
View evidence

Published literature

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
INDAPAMIDE Repurposing via ADORA2A Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
INDOMETHACIN Repurposing via ADORA2A Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
IRINOTECAN HYDROCHLORIDE Repurposing via ALOX5 Small molecule Approved Strong 95 — DGIdb —
ISOSORBIDE DINITRATE Repurposing via ADORA2A Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
ISTRADEFYLLINE Repurposing via ADORA2A Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
LAMOTRIGINE Repurposing via CACNA1H Small molecule Approved Strong 95 — DGIdb —
LEVODOPA Repurposing via ADORA2A Small molecule Approved Strong 95
4 pubs
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
MAFENIDE Repurposing via ADORA2A Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
MASOPROCOL Repurposing via ALOX5 Small molecule Approved Strong 95 — DGIdb —
MECAMYLAMINE Repurposing via ADORA2A Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
MECLOFENAMATE Repurposing via ALOX5 Small molecule Approved Strong 95 — DGIdb —
MECLOFENAMATE SODIUM Repurposing via ALOX5 Small molecule Approved Strong 95 — DGIdb ChEMBL Open Targets
MEFLOQUINE Repurposing via ADORA2A Small molecule Approved Strong 95 — DGIdb —
MESALAMINE Repurposing via ALOX5 Small molecule Approved Strong 95 — DGIdb —
METHAZOLAMIDE Repurposing via ADORA2A Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
METHOTREXATE Repurposing via ALOX5 Small molecule Approved Strong 95 — DGIdb —
METHOXSALEN Repurposing via ADORA2A Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
METHSUXIMIDE Repurposing via CACNA1G Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
METOPROLOL Repurposing via ADORA2A Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
MIANSERIN Repurposing via ADORA2A Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
MIBEFRADIL DIHYDROCHLORIDE Repurposing via CACNA1G Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb ChEMBL Open Targets
MILK THISTLE SEED EXTRACT Repurposing via ALOX5 Small molecule Approved Strong 95 — DGIdb —
MONTELUKAST SODIUM Repurposing via ALOX5 Small molecule Approved Strong 95 — DGIdb —
NAFTOPIDIL Repurposing via CACNA1H Small molecule Approved Strong 95 — DGIdb ChEMBL Open Targets
NALIDIXIC ACID Repurposing via ADORA2A Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
NICOTINE Repurposing via ADORA2A Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
NORFLOXACIN Repurposing via ADORA2A Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
OFLOXACIN Repurposing via ADORA2A Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
OLSALAZINE SODIUM Repurposing via ALOX5 Small molecule Approved Strong 95 — DGIdb ChEMBL Open Targets
OXTRIPHYLLINE Repurposing via ADORA2A Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
PARAMETHADIONE Repurposing via CACNA1G Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
PENTOXIFYLLINE Repurposing via ADORA2A Small molecule Approved Strong 95
2 trials 1 Trial pubs 1 RCT
View evidence

Registry trials

  • NCT04217733 — Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome (RECRUITING) PHASE3
  • NCT01542268 — Effect of Pentoxifylline on Tight Junctions (TJs) of Intestinal Mucosa in Patients With Irritable Bowel Syndrome(IBS) (UNKNOWN) PHASE4

Published literature

CT.gov search · Cochrane · PubMed

 DGIdb —
PHENSUXIMIDE Repurposing via CACNA1G Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
PHENYTOIN Repurposing via ADORA2A Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
PIMOZIDE Repurposing via CACNA1H Small molecule Approved Strong 95 — DGIdb —
PRAZOSIN Repurposing via ADORA2A Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
PREDNISOLONE Repurposing via CD40 Small molecule Approved Strong 95 — DGIdb —
PREGABALIN Repurposing via CACNA1G Small molecule Approved Strong 95
3 trials 1 Cochrane 2 Meta-analysis 5 Trial pubs 5 RCT
View evidence

Registry trials

  • NCT07635394 — Efficacy of Pregabalin for Patients With Irritable Bowel Syndrome (RECRUITING) NA
  • NCT00977197 — A Placebo-Controlled Trial of Pregabalin (Lyrica) for Irritable Bowel Syndrome (COMPLETED) PHASE2
  • NCT01331213 — Pregabalin on Colonic Motor and Sensory Function in Constipation Predominant Irritable Bowel Syndrome (COMPLETED) PHASE4

Published literature

CT.gov search · Cochrane · PubMed

 DGIdb —
PROGLUMIDE Repurposing via CCKAR Small molecule Approved Strong 95 — DGIdb —
REGADENOSON Repurposing via ADORA2A Small molecule Approved Strong 95 — DGIdb ChEMBL Open Targets
REGADENOSON ANHYDROUS Repurposing via ADORA2A Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
SELENIUM Repurposing via ALOX5 Small molecule Approved Strong 95 — DGIdb —
SINCALIDE Repurposing via CCKAR Small molecule Approved Strong 95 — DGIdb —
SIROLIMUS Repurposing via ADORA2A Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
SODIUM BICARBONATE Repurposing via CACNA1H Small molecule Approved Strong 95 — DGIdb —
STREPTOZOCIN Repurposing via CD40 Small molecule Approved Strong 95 — DGIdb —
SULBACTAM Repurposing via ADORA2A Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
SULFASALAZINE Repurposing via ALOX5 Small molecule Approved Strong 95 — DGIdb —
SULOCTIDIL Repurposing via CACNA1G Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb ChEMBL Open Targets
TACROLIMUS ANHYDROUS Repurposing via ADORA2A Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
TAZOBACTAM Repurposing via ADORA2A Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
TERODILINE HYDROCHLORIDE Repurposing via CACNA1G Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb ChEMBL Open Targets
THEOPHYLLINE Repurposing via ADORA2A Small molecule Approved Strong 95
3 pubs
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
THEOPHYLLINE SODIUM GLYCINATE Repurposing via ADORA2A Small molecule Approved Strong 95 — DGIdb ChEMBL Open Targets
TRIMETHADIONE Repurposing via CACNA1G Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
TROGLITAZONE Repurposing via ADORA2A Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
VALPROIC ACID Repurposing via CACNA1H Small molecule Approved Strong 95 — DGIdb —
VERAPAMIL Repurposing via CACNA1G Small molecule Approved Strong 95
1 trials
View evidence

Registry trials

  • NCT00552565 — Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D) (COMPLETED) PHASE3

CT.gov search · Cochrane · PubMed

 DGIdb —
VIDARABINE Repurposing via ADORA2B Small molecule Approved Strong 95 — DGIdb —
ZILEUTON Repurposing via ALOX5 Small molecule Approved Strong 95 — DGIdb —
ZONISAMIDE Repurposing via CACNA1G Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
DARAPLADIB Repurposing via ADORA2A Small molecule Phase III Moderate 70 — ChEMBL ChEMBL Open Targets
FENRETINIDE Repurposing via ADORA2A Small molecule Phase III Moderate 70 — ChEMBL ChEMBL Open Targets
BLESELUMAB Repurposing via CD40 Small molecule Phase II Emerging 50 — DGIdb ChEMBL Open Targets
CE-326597 Repurposing via CCKAR Small molecule Phase II Emerging 50 — DGIdb —
DEXLOXIGLUMIDE Repurposing via CCKAR Small molecule Phase II Emerging 50 — DGIdb —
ISCALIMAB Repurposing via CD40 Small molecule Phase II Emerging 50 — DGIdb —
MONOCLONAL ANTIBODY SGN-14 Repurposing via CD40 Small molecule Phase II Emerging 50 — DGIdb —
ALPRENOLOL Repurposing via ADORA2A Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
AMIFLOXACIN Repurposing via ADORA2A Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
BROLAMFETAMINE Repurposing via ADORA2A Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
CARZENIDE Repurposing via ADORA2A Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
DIFLOXACIN Repurposing via ADORA2A Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
DIMECAMINE Repurposing via ADORA2A Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
ELLAGIC ACID Repurposing via ADORA2A Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
ENISOPROST Repurposing via ADORA2A Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
FENCAMFAMIN Repurposing via ADORA2A Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
FLEROXACIN Repurposing via ADORA2A Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
IDOXIFENE Repurposing via ADORA2A Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
LYSERGIDE Repurposing via ADORA2A Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
MERAFLOXACIN Repurposing via ADORA2A Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
TENAMFETAMINE Repurposing via ADORA2A Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
ZIDAPAMIDE Repurposing via ADORA2A Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets

Natural Products

97 natural products with the same evidence schema as repurposed drugs — registry trials, PubMed literature, and reference links (pipeline-ranked). Only agents with direct clinical evidence are shown by default.

Reference lookups: Examine.com

DrugTypePhaseEvidence ScoreTrials & literatureSourcesLinks
Peppermint Natural product Botanical Phase III Moderate 29
8 trials 15 Cochrane 12 Meta-analysis 21 Trial pubs 16 RCT
View evidence

Registry trials

  • NCT05197413 — Study to Evaluate the Efficacy of Arrae's Bloat & Calm Alchemy Capsules to Reduce Bloating, Heartburn and Gas, and Alleviate the Intensity of IBS Symptoms (COMPLETED) NA
  • NCT06914921 — Enteric-Coated Peppermint Oil Versus Standard Antispasmodic in SLC6A4 (5-HTTLPR) Carriers With Irritable Bowel Syndrome. (COMPLETED) NA
  • NCT04484467 — Efficacy and Safety of a Food Supplement With Standardized Menthol, Limonene, and Gingerol Content in Patients With Irritable Bowel Syndrome (COMPLETED) NA
  • NCT02716285 — Peppermint Oil for the Treatment of Irritable Bowel Syndrome: Optimizing Therapeutic Strategies Using Targeted Delivery (COMPLETED) PHASE3
  • NCT05799053 — Peppermint Oil for the Treatment of Irritable Bowel Syndrome or Functional Abdominal Pain in Children: the MINT Study (COMPLETED) PHASE3
  • NCT01269671 — Efficacy of Combination Therapy vs Placebo for Pediatric Functional Abdominal Pain (WITHDRAWN) PHASE1
  • NCT02802241 — Effects of Open-label vs Double-blind Treatment in IBS (COMPLETED) NA
  • NCT02291445 — Comparing a 182mg Colon-targeted-delivery Peppermint Oil Capsule (Tempocol-ColoPulse®) and a 182mg Enteric-coated Peppermint Oil Capsule (Tempocol®), a Pharmacokinetic Study (COMPLETED) PHASE2

Published literature

CT.gov search · Cochrane · PubMed

 Examine.com Examine.com
Probiotics Natural product Probiotic Approved Moderate 26
8 trials 59 Cochrane 46 Meta-analysis 119 Trial pubs 105 RCT
View evidence

Registry trials

  • NCT05366335 — Colonoscopic Probiotics Infusion for Functional Gastrointestinal Disease (UNKNOWN) PHASE4
  • NCT07094035 — The Beneficial Effects on the Intestinal Function of a Food Supplement Based on an Extract of Green Tea and a Pool of Probiotics in Subjects With Irritable Bowel Syndrome With Predominance of Constipation (RECRUITING) NA
  • NCT03964103 — qQ-lab Daily-IBS for Irritable Bowel Syndrome (COMPLETED) NA
  • NCT04774042 — Probiotic Supplementation in the Dysbiosis of Bowel Preparation (UNKNOWN) NA
  • NCT01638208 — Changes in Gastrointestinal Microbiota Using VSL#3 in Patients With IBS-D (UNKNOWN) PHASE4
  • NCT05565612 — Clinical Trial to Evaluate the Effect of a Probiotic Mixture on Signs and Symptoms of Irritable Bowel Syndrome (COMPLETED) NA
  • NCT07584278 — Probiotics and Biomarkers in Irritable Bowel Syndrome (RECRUITING) NA
  • NCT06268964 — Exploring Treatments for Children's Abdominal Pain: Comparing Trimebutine and Probiotics (RECRUITING) PHASE1, PHASE2

Published literature

CT.gov search · Cochrane · PubMed

 ClinicalTrials.gov, Examine.com Examine.com
Vitamin D3 Natural product Nutraceutical Approved Moderate 20
8 trials 2 Trial pubs 2 RCT
View evidence

Registry trials

  • NCT01718925 — 25-hydroxyvitamin D and Fatigue: The VITALITY Study (COMPLETED)
  • NCT02579902 — Effect of Vitamin D3 Supplementation in Treatment of Irritable Bowel Syndrome (COMPLETED) PHASE1
  • NCT02419963 — Analyzing IBS to Identify Biomarkers and Microbiome Signatures (COMPLETED) NA
  • NCT05593367 — Effects of Vitamin D on Gut Microbiota, Intestinal Barrier in IBS-D Patients (UNKNOWN)
  • NCT03148288 — Vitamin D Supplementation in IBS (TERMINATED) NA
  • NCT07052890 — Curcumin, Vitamin D and Green Tea in IBS-D (COMPLETED) NA
  • NCT06123234 — Randomised Double-blind Active vs. Placebo Clinical Trial on the Effect of a Food Supplement on IBS in Children (UNKNOWN) NA
  • NCT02026518 — Effect of Cholecalciferol, Soy Isoflavones in Patients With Irritable Bowel Syndrome (COMPLETED) PHASE4

CT.gov search · Cochrane · PubMed

 Examine.com PubChem Examine.com
Vitamin D3 Natural product Nutraceutical Approved Emerging 19
8 trials 2 Trial pubs 2 RCT
View evidence

Registry trials

  • NCT01718925 — 25-hydroxyvitamin D and Fatigue: The VITALITY Study (COMPLETED)
  • NCT02579902 — Effect of Vitamin D3 Supplementation in Treatment of Irritable Bowel Syndrome (COMPLETED) PHASE1
  • NCT02419963 — Analyzing IBS to Identify Biomarkers and Microbiome Signatures (COMPLETED) NA
  • NCT05593367 — Effects of Vitamin D on Gut Microbiota, Intestinal Barrier in IBS-D Patients (UNKNOWN)
  • NCT03148288 — Vitamin D Supplementation in IBS (TERMINATED) NA
  • NCT07052890 — Curcumin, Vitamin D and Green Tea in IBS-D (COMPLETED) NA
  • NCT06123234 — Randomised Double-blind Active vs. Placebo Clinical Trial on the Effect of a Food Supplement on IBS in Children (UNKNOWN) NA
  • NCT02026518 — Effect of Cholecalciferol, Soy Isoflavones in Patients With Irritable Bowel Syndrome (COMPLETED) PHASE4

CT.gov search · Cochrane · PubMed

 Examine.com PubChem Examine.com
Psyllium Natural product Botanical Approved Emerging 19
8 trials 11 RCT
View evidence

Registry trials

  • NCT03265002 — Fibre and Gas in Irritable Bowel Syndrome (COMPLETED) NA
  • NCT06639984 — Psyllium in Pediatric IBS (RECRUITING) PHASE2
  • NCT04806386 — The Role of Fiber in the Prevention and Treatment of Fecal Incontinence (COMPLETED) NA
  • NCT05867550 — To Compare the Efficacy of Drugs in Combination for Treating Irritable Bowel Syndrome Associated With Diarrhea (COMPLETED) PHASE4
  • NCT02144753 — Use of Novel Prebiotic Fiber for Targeted Dietary Management of Irritable Bowel Syndrome (Nutrabiotix Phase II) (TERMINATED) PHASE2
  • NCT06551948 — Effect of MethylceIlulose or Psyllium on Fermentation of Inulin Assessed Using a Gas Sensing Capsule (COMPLETED) NA
  • NCT05619341 — Effect of Rate Of Delivery on Colonic Fermentation of inuliN (EON) (COMPLETED) NA
  • NCT00589771 — Saccharomyces Boulardii in Irritable Bowel Syndrome (COMPLETED) PHASE3

CT.gov search · Cochrane · PubMed

 ClinicalTrials.gov —
Pycnogenol Natural product Botanical Preclinical Moderate 17
1 pubs
View evidence

CT.gov search · Cochrane · PubMed

 Examine.com Examine.com
Curcumin Natural product Food compound Approved Moderate 17
7 trials 1 Meta-analysis 6 Trial pubs
View evidence

Registry trials

  • NCT05016596 — Postprandial Lipids in IBS and Nutritional Treatment (COMPLETED) NA
  • NCT04879810 — Plant Exosomes +/- Curcumin to Abrogate Symptoms of Inflammatory Bowel Disease (COMPLETED) NA
  • NCT00779493 — Curcumin (Tumeric) in the Treatment of Irritable Bowel Syndrome: A Randomized-Controlled Trial (COMPLETED) PHASE4
  • NCT06187298 — Effect of Oral Combined Berberine and Curcumin Pharmacological Therapy on IBS (COMPLETED)
  • NCT03568513 — Effect of Curcumin on Gut Microbiota in IBS (COMPLETED) NA
  • NCT07052890 — Curcumin, Vitamin D and Green Tea in IBS-D (COMPLETED) NA
  • NCT01167673 — The Effect of Coltect (Selenium, Curcumin and Green Tea) on Irritable Bowel Syndrome (UNKNOWN) PHASE2

Published literature

CT.gov search · Cochrane · PubMed

 Examine.com PubChem Examine.com
Melatonin Natural product Nutraceutical Phase III Moderate 17
5 trials 9 Trial pubs 8 RCT
View evidence

Registry trials

  • NCT01269671 — Efficacy of Combination Therapy vs Placebo for Pediatric Functional Abdominal Pain (WITHDRAWN) PHASE1
  • NCT00786123 — Exploring the Mechanism of a Probiotic Combination VSL#3 in Irritable Bowel Syndrome (COMPLETED) NA
  • NCT00790478 — Melatonin and Ulcerative Colitis: A Pilot Clinical Trial (TERMINATED) PHASE2
  • NCT01558284 — The Effect of Neu-P11 on Symptoms in Patients With D-IBS (COMPLETED)
  • NCT04193501 — Frequency of Sleep Abnormalities in Patients With Irritable Bowel Syndrome and Effect of Pharmacological Intervention (UNKNOWN) PHASE3

Published literature

CT.gov search · Cochrane · PubMed

 Examine.com PubChem Examine.com
Curcumin Natural product Food compound Approved Emerging 16
7 trials 1 Meta-analysis 6 Trial pubs
View evidence

Registry trials

  • NCT05016596 — Postprandial Lipids in IBS and Nutritional Treatment (COMPLETED) NA
  • NCT04879810 — Plant Exosomes +/- Curcumin to Abrogate Symptoms of Inflammatory Bowel Disease (COMPLETED) NA
  • NCT00779493 — Curcumin (Tumeric) in the Treatment of Irritable Bowel Syndrome: A Randomized-Controlled Trial (COMPLETED) PHASE4
  • NCT06187298 — Effect of Oral Combined Berberine and Curcumin Pharmacological Therapy on IBS (COMPLETED)
  • NCT03568513 — Effect of Curcumin on Gut Microbiota in IBS (COMPLETED) NA
  • NCT07052890 — Curcumin, Vitamin D and Green Tea in IBS-D (COMPLETED) NA
  • NCT01167673 — The Effect of Coltect (Selenium, Curcumin and Green Tea) on Irritable Bowel Syndrome (UNKNOWN) PHASE2

Published literature

CT.gov search · Cochrane · PubMed

 Examine.com PubChem Examine.com
Melatonin Natural product Nutraceutical Phase III Emerging 16
5 trials 9 Trial pubs 8 RCT
View evidence

Registry trials

  • NCT01269671 — Efficacy of Combination Therapy vs Placebo for Pediatric Functional Abdominal Pain (WITHDRAWN) PHASE1
  • NCT00786123 — Exploring the Mechanism of a Probiotic Combination VSL#3 in Irritable Bowel Syndrome (COMPLETED) NA
  • NCT00790478 — Melatonin and Ulcerative Colitis: A Pilot Clinical Trial (TERMINATED) PHASE2
  • NCT01558284 — The Effect of Neu-P11 on Symptoms in Patients With D-IBS (COMPLETED)
  • NCT04193501 — Frequency of Sleep Abnormalities in Patients With Irritable Bowel Syndrome and Effect of Pharmacological Intervention (UNKNOWN) PHASE3

Published literature

CT.gov search · Cochrane · PubMed

 Examine.com PubChem Examine.com
Senna Natural product Nutraceutical Preclinical Moderate 10
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 Examine.com Examine.com
Aloe Vera Natural product Nutraceutical Preclinical Moderate 10
1 trials 1 Meta-analysis
View evidence

Registry trials

  • NCT01400048 — Aloe Vera in Irritable Bowel Syndrome (COMPLETED) NA

CT.gov search · Cochrane · PubMed

 Examine.com Examine.com
Synbiotics Natural product Nutraceutical Phase II Moderate 10
6 trials 5 Cochrane
View evidence

Registry trials

  • NCT04598295 — SH-DS01 on Fecal Metagenomic Stability (COMPLETED) PHASE2
  • NCT07235228 — Effects of Vivatlac Synbiotic on Gut Micribiota of IBS Patients (RECRUITING) NA
  • NCT06647043 — Evaluate the Effect of Synbiotics in Irritable Bowel Syndrome (RECRUITING) NA
  • NCT07235215 — Vivatlac in Irritable Bowel Syndrome II (ViIBS2) (RECRUITING) NA
  • NCT07475299 — Synbiotic Supplement With Botanical Extracts for Gut Microbiota Balance in Irritable Bowel Syndrome (NOT_YET_RECRUITING) NA
  • NCT05731232 — Effects of Vivatlac Synbiotikum in Patients With Irritable Bowel Syndrome (COMPLETED) NA

Published literature

CT.gov search · Cochrane · PubMed

 Examine.com Examine.com
Zinc Natural product Nutraceutical Preclinical Emerging 10
1 trials 1 Cochrane 1 Trial pubs 1 RCT
View evidence

Registry trials

  • NCT01469936 — Effect of PERMEAPROTECT on the Quality of Life of Patients With Fibromyalgia (UNKNOWN) NA

CT.gov search · Cochrane · PubMed

 PubChem
Ginger Natural product Botanical Phase II Emerging 10
6 trials 4 RCT
View evidence

Registry trials

  • NCT04484467 — Efficacy and Safety of a Food Supplement With Standardized Menthol, Limonene, and Gingerol Content in Patients With Irritable Bowel Syndrome (COMPLETED) NA
  • NCT00676975 — The Efficacy of Tradition Chinese Medicine in Patients With Irritable Bowel Syndrome (COMPLETED) PHASE2
  • NCT04340661 — Effects of a Food Supplement Composed by BIOintestil ® (Bionocol®) on Microbiota and Inflammatory Profile in Irritable Bowel Syndrome Patients (TERMINATED) NA
  • NCT04312477 — Efficacy and Safety of Modified Gegen Qinlian Decoction for Diarrhea-predominant Irritable Boewl Syndrome (UNKNOWN) EARLY_PHASE1
  • NCT04879810 — Plant Exosomes +/- Curcumin to Abrogate Symptoms of Inflammatory Bowel Disease (COMPLETED) NA
  • NCT07475299 — Synbiotic Supplement With Botanical Extracts for Gut Microbiota Balance in Irritable Bowel Syndrome (NOT_YET_RECRUITING) NA

Published literature

CT.gov search · Cochrane · PubMed

 PubChem
Lactobacillus Natural product Probiotic Approved Emerging 7
8 trials
View evidence

Registry trials

  • NCT05366335 — Colonoscopic Probiotics Infusion for Functional Gastrointestinal Disease (UNKNOWN) PHASE4
  • NCT07094035 — The Beneficial Effects on the Intestinal Function of a Food Supplement Based on an Extract of Green Tea and a Pool of Probiotics in Subjects With Irritable Bowel Syndrome With Predominance of Constipation (RECRUITING) NA
  • NCT01638208 — Changes in Gastrointestinal Microbiota Using VSL#3 in Patients With IBS-D (UNKNOWN) PHASE4
  • NCT07584278 — Probiotics and Biomarkers in Irritable Bowel Syndrome (RECRUITING) NA
  • NCT06268964 — Exploring Treatments for Children's Abdominal Pain: Comparing Trimebutine and Probiotics (RECRUITING) PHASE1, PHASE2
  • NCT01545037 — Effect of BIO-K+ on Symptoms of Irritable Bowel Syndrome (COMPLETED) PHASE2
  • NCT06271538 — Evaluation of Efficacy of Skål Pro Powder on Symptoms of Irritable Bowel Syndrome (RECRUITING) PHASE4
  • NCT05864716 — Colonoscopic Probiotics Spray in Irritable Bowel Syndrome (UNKNOWN) NA

CT.gov search · Cochrane · PubMed

 —
Boswellia Natural product Botanical Phase III Emerging 7
3 trials 2 RCT
View evidence

Registry trials

  • NCT06423586 — Effect of Lecithin-based Curcuma and Boswellia on Post-acute COVID-19 IBS (COMPLETED) NA
  • NCT07576634 — Effects of Standardized Boswellia Carterii Extract on Irritable Bowel Syndrome Patients (COMPLETED) PHASE2, PHASE3
  • NCT06407609 — Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS (COMPLETED) NA

Published literature

CT.gov search · Cochrane · PubMed

 PubChem
Berberine Natural product Botanical Preclinical Emerging 7
1 trials 1 Trial pubs
View evidence

Registry trials

  • NCT06187298 — Effect of Oral Combined Berberine and Curcumin Pharmacological Therapy on IBS (COMPLETED)

CT.gov search · Cochrane · PubMed

 PubChem
Selenium Natural product Nutraceutical Phase II Emerging 7
1 trials 1 Cochrane 1 RCT
View evidence

Registry trials

  • NCT01167673 — The Effect of Coltect (Selenium, Curcumin and Green Tea) on Irritable Bowel Syndrome (UNKNOWN) PHASE2

Published literature

CT.gov search · Cochrane · PubMed

 PubChem
Spirulina Natural product Nutraceutical Preclinical Emerging 7
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 —
Niacin Natural product Nutraceutical Preclinical Emerging 7 — PubChem
Cgs-15943 Natural product Food compound Preclinical Emerging 0 — ChEMBL ChEMBL PubChem ChEMBL
Methscopolamine Natural product Food compound Preclinical Emerging 0 — ChEMBL ChEMBL PubChem ChEMBL
Himbacine Natural product Food compound Preclinical Emerging 0 — ChEMBL ChEMBL PubChem ChEMBL
Carbachol Natural product Food compound Preclinical Emerging 0 — ChEMBL ChEMBL PubChem ChEMBL
Oxotremorine Natural product Food compound Preclinical Emerging 0 — ChEMBL ChEMBL PubChem ChEMBL
Muscarine Natural product Food compound Preclinical Emerging 0 — ChEMBL ChEMBL PubChem ChEMBL
Neca Natural product Food compound Preclinical Emerging 0 — ChEMBL ChEMBL PubChem ChEMBL
Zm-241385 Natural product Food compound Preclinical Emerging 0 — ChEMBL ChEMBL PubChem ChEMBL
8-PHENYL Theophylline Natural product Food compound Preclinical Emerging 0 — ChEMBL ChEMBL PubChem ChEMBL
Zileuton Natural product Food compound Preclinical Emerging 0 — ChEMBL ChEMBL PubChem ChEMBL
Sincalide Natural product Food compound Preclinical Emerging 0 — ChEMBL ChEMBL PubChem ChEMBL
L-365260 Natural product Food compound Preclinical Emerging 0 — ChEMBL ChEMBL PubChem ChEMBL
Arecoline Natural product Food compound Preclinical Emerging 0 — ChEMBL ChEMBL PubChem ChEMBL
Atropine Natural product Food compound Preclinical Emerging 0 — ChEMBL ChEMBL PubChem ChEMBL
(2R,4R,5R)-2-[[(2R,4R,5R)-2-[[(2R,4R,5R)-3,4-dihydroxy-2,5-dimethylol-tetrahydrofuran-2-yl]oxymethyl]-3,4-dihydroxy-5-methylol-tetrahydrofuran-2-yl]oxymethyl]-5-methylol-tetrahydrofuran-2,3,4-triol Natural product Food compound Preclinical Emerging 0 — ClinicalTrials.gov PubChem
(3R,4S,5S,6R)-6-methyloltetrahydropyran-2,3,4,5-tetrol Natural product Food compound Preclinical Emerging 0 — ClinicalTrials.gov PubChem
Lactobacillus Paracasei Natural product Nutraceutical Preclinical Emerging 0 — —
Escherichia Coli (Probiotic Variety) Natural product Nutraceutical Preclinical Emerging 0 — —
Bifidobacterium Longum Natural product Nutraceutical Preclinical Emerging 0 — —
Kiwifruit Natural product Nutraceutical Preclinical Emerging 0 — —
Lactobacillus Probiotics Natural product Nutraceutical Preclinical Emerging 0 — —
Lactobacillus Gasseri Natural product Nutraceutical Preclinical Emerging 0 — —
Lactobacillus Plantarum Natural product Nutraceutical Preclinical Emerging 0 — —
Bifidobacterium Animalis Natural product Nutraceutical Preclinical Emerging 0 — —
Palmitoylethanolamide Natural product Nutraceutical Preclinical Emerging 0 — —
Lactobacillus Casei Natural product Nutraceutical Preclinical Emerging 0 — —
Fiber Natural product Nutraceutical Preclinical Emerging 0 — —
Patchouli Natural product Nutraceutical Preclinical Emerging 0 — —
Paeoniflorin Natural product Nutraceutical Preclinical Emerging 0 — —
Coriandrum Sativum Natural product Nutraceutical Preclinical Emerging 0 — —
Enterococcus Faecium Natural product Nutraceutical Preclinical Emerging 0 — —
Propionibacterium Freudenreichii Natural product Nutraceutical Preclinical Emerging 0 — —
Homeopathic Medicine: All Natural product Nutraceutical Preclinical Emerging 0 — —
Artichoke Natural product Nutraceutical Preclinical Emerging 0 — —
Bifidobacterium Infantis Natural product Nutraceutical Preclinical Emerging 0 — —
Bacillus Coagulans Natural product Nutraceutical Preclinical Emerging 0 — —
Bacillus Subtilis Natural product Nutraceutical Preclinical Emerging 0 — —
Geraniol Natural product Nutraceutical Preclinical Emerging 0 — —
Kombucha Tea Natural product Nutraceutical Preclinical Emerging 0 — —
Lemon Balm Natural product Nutraceutical Preclinical Emerging 0 — —
Moxibustion Natural product Nutraceutical Preclinical Emerging 0 — —
Guar Gum Natural product Nutraceutical Preclinical Emerging 0 — —
Zeolite Natural product Nutraceutical Preclinical Emerging 0 — —
Beta-Glucan Natural product Nutraceutical Preclinical Emerging 0 — —
Zataria Multiflora Natural product Nutraceutical Preclinical Emerging 0 — —
Poria Cocos Natural product Nutraceutical Preclinical Emerging 0 — —
Polyphenols Natural product Nutraceutical Preclinical Emerging 0 — —
Iberogast Natural product Nutraceutical Preclinical Emerging 0 — —
Fennel Natural product Nutraceutical Preclinical Emerging 0 — —
Melissa (Lemonbalm) Natural product Nutraceutical Preclinical Emerging 0 — —
Mentha Spicata Natural product Nutraceutical Preclinical Emerging 0 — —
Bifidobacterium Lactis Natural product Nutraceutical Preclinical Emerging 0 — —
Bifidobacterium Breve Natural product Nutraceutical Preclinical Emerging 0 — —
Arrowroot Natural product Nutraceutical Preclinical Emerging 0 — —
Streptococcus Faecium Natural product Nutraceutical Preclinical Emerging 0 — —
Charcoal Natural product Nutraceutical Preclinical Emerging 0 — —
Bee Propolis Natural product Nutraceutical Preclinical Emerging 0 — —
Ellagic Acid Natural product Nutraceutical Preclinical Emerging 0 — —
Lactobacillus Brevis Natural product Nutraceutical Preclinical Emerging 0 — —

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.